ASIC SHORTING DATA for Clinuvel CUV

In the face of good news for Clinuvel on many fronts, including their competition getting an FDA CRL rejection, it can be observed from ASIC data that a massive short selling attack is underway on CUV. Here is the breakdown of the evidence, it is important to remember this is fake sell liquidity introduced into a very small company that is very profitable and has peer leading financial performance, has not partnered with Big pharma, has massive cash (~$240 Million), extremely low valuation (sub 10 P/E with cash removed), still growing, self funding an excellent blockbuster pipeline and still producing profits while completing a 210 patient phase 3.

Average analyst Price targets over $25, best comparison in a totally inferior company called Disc valued at $3.5 Billion (and Disc burn about $1 Million each day just to HOPE to enter small EPP market with their lead drug). At Clinuvel it is mostly not real holders selling IMO when the near term potential is so massive, it is a controlled short attack with fake sell liquidity via borrowed shares to destroy the valuation of CUV and ASIC data each day provides evidence for this. Personally I still believe it is to facilitate a takeover at some point. Whatever the reason it is interesting to observe this all play out, Clinuvel are in their strongest position ever and are even going to apply for a totally new drug into a new market in just months. Also worth mentioning the imminent NASDAQ listing which they have spent a significant sum on and this will put them side by side with Disc.

In most recent 10 days of ASIC data shorting increased by >250000 new open short positions (from 16/02 - 02/03 increase 7.07% to 7.57%).

In almost exactly one year shorting increased by about 1.1 Million new open short positions (from 11/3/25 - 02/3/26 increase 5.34% to 7.57%).

In last 2.5 years shorting increased by incredible 2.4 Million new open short positions (from 18/9/23 - 02/3/26 increase 2.73% to 7.57%).

Total short positions are now 7.57% or about 3.8 Million shares.

There are only approx 50 Million CUV shares on issue which is an extremely low base.

This is an amazing, sustained short attack on a company that has peer leading financial performance year after year and keeps producing great profits while self funding a great pipeline and their own established low cost distribution network. Clinuvel is the only company treating a rare and terrible disease, including for children, and their next indication for an already FDA, EMA approved drug is for a massive market in Vitiligo. Even the new Neuracthel drug will enter a market with a larger TAM than EPP if approved.

Every day it can be observed how tightly controlled the share price action is with CUV. When Disc failed at the FDA and investors come for CUV the shorts pump in fake Sell liquidity to limit any price appreciation. This happens regularly on great profit news, pipeline milestones, CUV105 photographic evidence etc. It's also worth mentioning how Clinuvel can do A LOT for shareholders to protect their interests from this short attack. They have a 1.5 Million share buyback which they continue to not implement despite shareholder cash growing all the time, despite clear share price manipulation and despite value destruction on a massive scale. This is also very weird when they tightly control everything else about this company but seemingly allow the share price to get junked in a systematic manner. No one can say the share buyback failed, it just hasn't been implemented. Fix this issue and Clinuvel will have even stronger financial fundamentals than any peer company with permanent benefits flowing from less shares to spread profits amongst. PW, in a rare move for an ASX CEO, announced his belief in attaining an elusive $7.5 Billion valuation based on Clinuvel potential - I interpret this as an extremely bullish signal. Based on this it seems logical to deploy that rather tiny percentage of shareholder capital towards buying CUV as they announced, because I bet they never find an acquisition as good as they are right now.

All IMO DYOR